WW doomed by GLP-1s?

Hong Kong Yanpep International
The 'obesity becomes optional' framing for the post-patent landscape is probably optimistic about both distribution and adoption, but as a directional claim about where the public health trajectory is heading it holds up. The infrastructure question of who gets access once cost drops is the actual challenge.
 
The hyperfixation on GLP-1 as the single mechanism is a good point. The commercial response trying to replicate the effect through supplements or natural approaches is chasing the outcome without understanding the receptor pathway. WW's challenge is that their model assumed the behavioral modification piece was the bottleneck when for most people it wasn't.
 
Back
Top